Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 11, 2026, details the results of the 2026 Annual Meeting of Stockholders held on that date. The Company, incorporated in Delaware, reported on six proposals submitted to its security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
As of the Record Date (April 14, 2026), 188,638,866 shares were outstanding. At the Annual Meeting, 141,927,939 shares were represented, constituting a quorum. All six proposals were approved by stockholders:
- Proposal 1 (Directors): Elected seven nominees (Collard, Cusack, Dissanaike, Johnson, Kaseta, Morgan, Waage) to serve until the 2027 Annual Meeting.
- Proposal 2 (Auditor): Ratified the appointment of Withum Smith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (Executive Compensation): Approved, on a nonbinding advisory basis, the compensation paid to Named Executive Officers for the fiscal year ended December 31, 2025.
- Proposal 4 (Equity Incentive Plan): Approved the amendment and restatement of the 2007 Equity Incentive Plan, increasing authorized shares by an additional 16,560,000.
- Proposal 5 (ESPP): Approved the amendment to the 1997 Employee Stock Purchase Plan, increasing authorized shares by an additional 10,000,000.
- Proposal 6 (Tax Benefits): Ratified, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of the voting process.
Investor Verification Checklist
- Verify the impact of the 26,560,000 additional shares authorized under Proposals 4 and 5 on potential future dilution.
- Review the specific terms of the newly adopted Tax Benefits Preservation Plan.
- Confirm the tenure of the newly elected board members through the 2027 Annual Meeting.
- Check subsequent filings for the Company's financial results for the fiscal year ended December 31, 2025, referenced in the executive compensation vote.